Drugs / Ribavirin
Ribavirin
also known as
RBV · Copegus · Rebetol · Virazole · SCH 18908 · SCH 018908 · (b) SCH 18908, PEGETRON (ribavirin) Capsules · COPEGUS (RIBAVIRIN) · +14 more
Small molecule targets EIF4E
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Rebetol | — | 2023-10-18 | europa.eu ↗ |
| Label expansions (3) | US (FDA) | COPEGUS | — | 2005-02-25 – 2011-08-09 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | REBETOL | — | 1998-12-09 – 2002-03-06 | fda.gov ↗ |
| Approved | EU (EMA) | Rebetol | — | 1999-05-06 | europa.eu ↗ |
| Label expansion | US (FDA) | VIRAZOLE | — | 1993-02-05 | fda.gov ↗ |
| Approved | US (FDA) | VIRAZOLE | — | 1985-12-31 | fda.gov ↗ |
Trials 433 · started per year
today
US approved 1985
EU approved 1999
1
1
1
2
3
1
2
7
14
21
21
26
16
25
11
20
13
24
37
48
38
31
28
8
9
3
1
5
2
2
2
1
1985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
News releases announcing trial results or a regulatory action · 151
| Date | Issuer | Release |
|---|---|---|
| 2020-01-31 | AbbVie | Regulatory AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis abbvie.com ↗
Today's positive CHMP opinion for MAVIRET moves us further toward our goal of providing an effective 8-week therapeutic option with the potential to simplify the treatment journey for the majority of people living with HCV, regardless of disease genotype. |
| 2019-11-08 | Gilead Sciences | Results Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019 gilead.com ↗ |
| 2019-10-21 | Ascletis Pharmaceuticals Co., Ltd. | Results Manuscript Publication of the First All-oral DAA HCV Regimen Developed by Ascletis from China in the Journal of Clinical and Translational Hepatology ascletis.com ↗
The RDV/DNVr regimen was with good safety and tolerability. |
| 2019-04-11 | Gilead Sciences | Results Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019 gilead.com ↗
No grade 3-4 serious adverse events or deaths in the study were considered to be related to study drug. |
| 2018-11-06 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis to Present Phase II / III Clinical Study for Its Innovative All-oral HCV Treatment at the 69th Annual meeting of AASLD ascletis.com ↗
The results show that RDV/DNV Regimen demonstrated a cure rate of 99% (SVR12) with a short treatment duration of 12 weeks in treatment-naïve non-cirrhotic HCV genotype 1 Chinese patients. |
| 2018-05-30 | Gilead Sciences | Regulatory China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection gilead.com ↗
The CDA also approved Epclusa in combination with ribavirin (RBV) for adults with HCV and decompensated cirrhosis. |
| 2017-09-27 | AbbVie | Regulatory AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan abbvie.com ↗
AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved MAVIRET™ (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). |
| 2017-08-03 | AbbVie | Regulatory AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks abbvie.com ↗
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved MAVYRET™ (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6). |
| 2017-06-23 | AbbVie | Regulatory AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) abbvie.com ↗ |
| 2017-04-22 | Merck Sharp & Dohme LLC | Results Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C merck.com ↗ |
| 2017-04-21 | AbbVie | Results Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C abbvie.com ↗
In results from the Phase 3 ENDURANCE-3 study, 95 percent (n=149/157) of GT3 chronic HCV infected patients without cirrhosis and who are new to treatment achieved sustained virologic response at 12 weeks post-treatment (SVR 12 ) following 8 weeks of treatment with G/P. |
| 2017-04-20 | AbbVie | Results AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis abbvie.com ↗
SVR 12 was achieved by 145/146 (99 percent) patients, with one GT1a-infected patient experiencing relapse. |
| 2017-03-24 | Chugai Pharmaceutical | Regulatory Approval of Antiviral Drug, COPEGUS ® for Additional Indication for Improvement of Viraemia in Patients with neither Serogroup 1 nor 2 Chronic Hepatitis C or Compensated Cirrhosis Related to Hepatitis C chugai-pharm.co.jp ↗
With the approval, the combination therapy of Copegus and sofosbuvir is available for all patients except serogroup 1 (genotype 1) with chronic hepatitis C or compensated cirrhosis related to hepatitis C. |
| 2017-03-14 | AbbVie | Regulatory AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C abbvie.com ↗
We are pleased that G/P has now been recognized as a potential important therapy for people living with HCV through the receipt of priority review designations by regulatory authorities in Japan , the EU and the U.S. |
| 2016-11-15 | AbbVie | Results AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease abbvie.com ↗
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients with severe chronic kidney disease (CKD) achieved sustained virologic response following 12 weeks of treatment (SVR 12 ) with its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in the primary intent-to-treat (ITT) analysis. |
| 2016-07-25 | AbbVie | Regulatory CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) abbvie.com ↗ |
| 2016-04-16 | Gilead Sciences | Results Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies gilead.com ↗
Poster SAT-138 highlighted combined safety and efficacy results from Studies 1168 and 1169 evaluating SOF/VEL plus GS-9857, with or without ribavirin, in genotype 1-6, treatment-naïve patients, with and without cirrhosis. |
| 2016-04-15 | AbbVie | Results AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals abbvie.com ↗
SVR 12 was achieved in 95 percent of patients with and without RBV (n=20/21, n=19/20; respectively) in a modified intent-to-treat analysis, excluding patients who did not achieve SVR for reasons other than virologic failure. |
| 2016-04-15 | AbbVie | Results AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry abbvie.com ↗
These data support results seen in Phase 3 clinical trials for chronic GT1 or GT4 hepatitis C virus (HCV) infected patients treated with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) with or without ribavirin (RBV). |
| 2016-04-14 | AbbVie | Results AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients abbvie.com ↗
Results also showed 97 percent of patients with genotype 1a (GT1a) chronic HCV infection with or without baseline NS5A RAVs (n=57/59 and n=351/361 respectively) achieved SVR 48 when receiving the recommended regimen of VIEKIRAX + EXVIERA with RBV. |
| 2016-04-13 | Merck Sharp & Dohme LLC | Results Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial merck.com ↗
In this study, ZEPATIER demonstrated superiority on efficacy and safety endpoints compared to sofosbuvir plus pegIFN/RBV, based on pre-specified analyses. |
| 2016-03-30 | AbbVie | Results AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016 abbvie.com ↗
Ombitasvir/Paritaprevir/Ritonavir With Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egyptian Adults With Chronic HCV Genotype 4 Infection (AGATE-II) |
| 2015-11-16 | Bristol-Myers Squibb | Results Data from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis Presented at AASLD bms.com ↗
Daclatasvir+sofosbuvir+ribavirin regimen for 12 or 16 weeks achieved SVR12 rates of 88% and 92%, respectively, in genotype 3 patients with advanced fibrosis or cirrhosis |
| 2015-11-16 | AbbVie | Results AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C abbvie.com ↗
After 12 weeks of treatment, SVR 12 rates achieved were 97-100 percent in genotype 1 (GT1), 96-100 percent in genotype 2 (GT2) and 83-94 percent in genotype 3 (GT3) patients. |
| 2015-11-15 | Merck Sharp & Dohme LLC | Results Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting® merck.com ↗
Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved virologic cure rates of 91 percent (74/81) and 89 percent (48/54), respectively. |
| 2015-11-14 | AbbVie | Results AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis abbvie.com ↗
Results show that 95 percent (n=586/615) of patients in the TOPAZ-II trial achieved a sustained virologic response at 12 weeks post-treatment (SVR 12 ) after 12 or 24 weeks of treatment, a secondary endpoint for the study. |
| 2015-09-11 | AbbVie | Results Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Genotype 1 Hepatitis C Patients abbvie.com ↗
This study of Polish patients who reached post-treatment at week 12 (n=40 of 186 enrolled to date), demonstrated 98 percent (n=39/40) SVR 12 . |
| 2015-07-24 | AbbVie | Regulatory TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. abbvie.com ↗
TECHNIVIE is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. |
| 2015-04-25 | Merck Sharp & Dohme LLC | Results Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir at the International Liver CongressTM 2015 merck.com ↗
Following 12 weeks of treatment with a combination of grazoprevir and elbasvir plus RBV, 96 percent of the patients (76/79) with chronic HCV GT1 infection who had failed prior treatment with specified DAA-based regimens achieved SVR12. |
| 2015-04-25 | Gilead Sciences | Results Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5 gilead.com ↗
Results from the BOSON study of Sovaldi ® (sofosbuvir 400 mg) in combination with ribavirin (RBV) or with pegylated interferon (PEG)/RBV demonstrated high cure rates across all patients with genotypes 2 and 3. |
| 2015-04-25 | Bristol-Myers Squibb | Results ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B) bms.com ↗
The study’s primary endpoints were reached, with 95% of post-transplant genotype 1 patients and 82% of genotype 1 patients with advanced cirrhosis achieving SVR12. |
| 2015-04-25 | AbbVie | Results AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015 abbvie.com ↗
Patients who reached post-treatment week four to date (n=10 of 20 enrolled) achieved 100 percent SVR 4 (n=10/10). |
| 2015-04-24 | AbbVie | Regulatory U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C abbvie.com ↗
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). |
| 2015-04-23 | Merck Sharp & Dohme LLC | Results Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection merck.com ↗
HCV infected, treatment-experienced patients ( C-EDGE TE ) treated with or without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent (98/104) and 92 percent (97/105), respectively |
| 2015-04-23 | Gilead Sciences | Results Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease gilead.com ↗ |
| 2015-04-13 | Ascletis Pharmaceuticals Co., Ltd. | Results HCV RACE IN CHINA ascletis.com ↗
In 30 non-cirrhotic patients with genotype 1b infection, 97% achieved an SVR12. |
| 2015-03-23 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis’ triple therapy HCV drug nails phase II trial in Chinese patients ascletis.com ↗
The study results indicate that ASC08, in combination with peginterferon alfa 2a plus ribavirin, can deliver better cure rate in Chinese patients where genotype 1b predominates, as compared to Caucasian patients where genotype 1a predominates, |
| 2015-02-23 | AbbVie | Results Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Confere abbvie.com ↗
The SVR 12 rates were 91 percent (n=51/56) for subjects with HCV GT1a infection and 100 percent (n=7/7) for those with HCV GT1b infection. |
| 2014-11-21 | AbbVie | Regulatory CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe abbvie.com ↗ |
| 2014-11-11 | Merck Sharp & Dohme LLC | Results Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naïve and Difficult-to-Cure Patients merck.com ↗
The final results were presented in oral sessions at the 65 th American Association for the Study of Liver Diseases (AASLD) Annual Meeting (also known as The Liver Meeting ® ) and published as separate papers online in The Lancet . |
| 2014-11-11 | Gilead Sciences | Results Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C gilead.com ↗
Rates of sustained virologic response (SVR12) ranged from 88 percent to 100 percent among those receiving SOF plus GS-5816 100 mg for 12 weeks – the regimen selected for Phase 3 studies. |
| 2014-11-11 | AbbVie | Results AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014 abbvie.com ↗
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014. |
| 2014-11-11 | AbbVie | Results AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014 abbvie.com ↗
100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR 12 ) |
| 2014-11-08 | Bristol-Myers Squibb | Results Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis bms.com ↗
Daclatasvir TRIO achieves 98% cure rate in treatment-naïve and 93% cure rate in treatment-experienced genotype 1 patients with cirrhosis when used with ribavirin, as shown in UNITY 2 |
| 2014-06-17 | AbbVie | Regulatory European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C abbvie.com ↗
Validation of the MAAs confirms that the submissions are complete and starts the EMA's centralized review process. |
| 2014-04-22 | AbbVie | Regulatory AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C abbvie.com ↗
AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. |
| 2014-04-12 | Janssen Research & Development, LLC | Results Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) jnj.com ↗
Final results from cohort 2 of the Phase 2 COSMOS study demonstrated that 93 percent of patients with genotype 1 HCV and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated with simeprevir and sofosbuvir for 12 weeks achieved sustained virologic response 12 weeks after the end of treatment (SVR12). |
| 2014-04-12 | AbbVie | Results AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™ abbvie.com ↗
Patients achieved sustained virologic response rates 12 weeks post-treatment (SVR 12 ) of 91.8 percent and 95.9 percent in the 12-week and 24-week treatment arms, respectively. |
| 2014-04-11 | Gilead Sciences | Results Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease gilead.com ↗
Of the 22 patients who completed 24 weeks of therapy, 95 percent (n=21/22) achieved virologic suppression on treatment. |
| 2014-04-11 | AbbVie | Results AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™ abbvie.com ↗
These data show very promising results in people who are infected with either subtype of the GT1 hepatitis C virus and who are either new to therapy or treatment-experienced. |
| 2014-04-10 | Merck Sharp & Dohme LLC | Results Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection merck.com ↗
Interim analysis of hard-to-cure 1 patients administered MK-5172/MK-8742 with and without ribavirin (RBV) for 12 or 18 weeks showed sustained viral response 2 (SVR), 4 to 8 weeks after the completion of therapy (SVR4/8): |
| 2014-04-10 | Gilead Sciences | Results Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy gilead.com ↗
Among the 50 patients for whom sustained virologic response data was available 12 weeks after the end of treatment (SVR12), 74 percent (n=37/50) achieved SVR12. |
| 2014-04-09 | Merck Sharp & Dohme LLC | Results Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection merck.com ↗
a sustained viral response 1 (SVR) was observed in 98 percent (42/43) of patients administered MK-5172/MK-8742 alone and 94 percent (75/80) in those administered MK-5172/MK-8742 plus RBV. |
| 2014-03-05 | Merck Sharp & Dohme LLC | Results Merck’s Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection merck.com ↗
In these co-infected patients, the administration of MK-5172/MK-8742 for 12 weeks resulted in robust HCV suppression, and a safety profile consistent with that observed for patients infected with HCV Genotype 1 infection (GT1) alone. |
| 2013-12-10 | AbbVie | Results AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C abbvie.com ↗
In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR 12 ) with the regimen. |
| 2013-11-18 | AbbVie | Results AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy abbvie.com ↗
In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR 12 ) of 96 percent. |
| 2013-11-02 | Boehringer Ingelheim | Results Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV prnewswire.com ↗
In comparison, 50% (131/264) of patients treated with PegIFN/RBV alone achieved SVR12. |
| 2013-11-02 | Boehringer Ingelheim | Results Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising interim Phase 2a data prnewswire.com ↗
all patients (13/13) who reached the 4-week post-treatment follow-up had undetectable levels of hepatitis C virus (SVR4) with an investigational, 12-week, all-oral regimen of faldaprevir and deleobuvir, in combination with Presidio's pan-genotypic NS5A inhibitor, PPI-668, with ribavirin |
| 2013-11-02 | Merck Sharp & Dohme LLC | Results Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting merck.com ↗
Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied |
| 2013-11-02 | Gilead Sciences | Results Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation gilead.com ↗ |
| 2013-11-02 | Gilead Sciences | Results Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients gilead.com ↗
In the Phase 3 VALENCE study, 85 percent (n=212/250) of treatment-naïve or treatment-experienced patients with genotype 3 HCV who received a 24-week regimen of sofosbuvir plus ribavirin (RBV) achieved a sustained virologic response 12 weeks after treatment (SVR12). |
| 2013-10-08 | Boehringer Ingelheim | Results Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase 2 trial prnewswire.com ↗
Additionally, 100 percent of patients who have completed treatment (13/13) achieved non-detectable levels of virus at the end of treatment. |
| 2013-07-25 | Vertex Pharmaceuticals Incorporated | Results Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C vrtx.com ↗
Vertex recently completed dosing of 100 mg and 200 mg of VX-135 in combination with ribavirin as part of the 12-week Phase 2 study in Europe, and both doses were well tolerated with no discontinuations. |
| 2013-05-21 | Janssen Research & Development, LLC | Results Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients jnj.com ↗
In the simeprevir arm, on-treatment failure rates were 3 percent and relapse rates were 19 percent, compared to 27 percent and 48 percent in the placebo arm. |
| 2013-05-06 | AbbVie | Regulatory AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration abbvie.com ↗
AbbVie is pleased that the FDA has granted Breakthrough Therapy designation to our 3-DAA combination with and without ribavirin. |
| 2013-05-02 | Gilead Sciences | Results Gilead Reports Interim Data From Phase 2 LONESTAR Study gilead.com ↗ |
| 2013-04-23 | Boehringer Ingelheim | Results Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 Percent of Patients with Hepatitis C in Phase 3 Pivotal Trial prnewswire.com ↗
In previously untreated patients with genotype-1 hepatitis C virus (HCV) who received once-daily faldaprevir plus PegIFN/RBV, 79% and 80% in the 120mg and 240mg arms, respectively, achieved viral cure when measured 12 weeks after treatment was completed (SVR12). |
| 2013-04-23 | Boehringer Ingelheim | Results Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 per cent of Patients with Hepatitis C in Phase 3 Pivotal Trial(1) prnewswire.com ↗
In previously untreated patients with genotype-1 hepatitis C virus (HCV) who received once-daily faldaprevir plus PegIFN/RBV, 79% and 80% in the 120mg and 240mg arms, respectively, achieved viral cure when measured 12 weeks after treatment was completed (SVR12). |
| 2013-04-23 | Merck Sharp & Dohme LLC | Results Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ merck.com ↗
the rates of sustained viral response (SVR) at week 24 follow-up (SVR24) were 86 percent (55/64) and 92 percent (61/66) for the MK-5172 100 mg plus PR and MK-5172 200 mg plus PR arms |
| 2013-04-23 | Janssen Research & Development, LLC | Results Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients jnj.com ↗
In both studies, 50 percent of patients receiving pegylated interferon and ribavirin alone achieved SVR12. |
| 2013-04-23 | Gilead Sciences | Results Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C To Be Presented at 48th Annual EASL Meeting; Findings Published Online Today in The New England Journal of Medicine gilead.com ↗
Overall SVR12 rates (sustained viral response 12 weeks after completing therapy) from 50 to 90 percent were observed. |
| 2013-04-23 | Vertex Pharmaceuticals Incorporated | Results ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection vrtx.com ↗
Results of seven-day viral kinetic evaluations of ALS-2200 in treatment-naïve people with chronic HCV infection are included in the following table: |
| 2013-04-08 | Merck Sharp & Dohme LLC | Results Merck to Present New Data on VICTRELIS® (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting merck.com ↗
High Sustained Viral Response at 12- and 24-week follow-up of MK-5172 with Pegylated Interferon alfa-2b and Ribavirin (PR) in HCV Genotype 1 Treatment-naïve Non-cirrhotic Patients. |
| 2013-02-19 | Gilead Sciences | Results Gilead’s Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study gilead.com ↗
The study met its primary efficacy endpoint of superiority compared to a predefined historic control sustained virologic response (SVR) rate of 25 percent. |
| 2013-02-04 | Gilead Sciences | Results Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C gilead.com ↗
All common adverse events (≥10 percent in any group) occurred more frequently in subjects receiving peg-IFN and RBV as compared to sofosbuvir and RBV. |
| 2013-01-07 | Gilead Sciences | Results Gilead Provides Update on Hepatitis C Development Programs gilead.com ↗
Sustained Virologic Response Achieved with Oral Regimen of Sofosbuvir, GS-5885 and Ribavirin in 9/9 Null Responder Genotype 1 Hepatitis C Patients |
| 2012-11-27 | Gilead Sciences | Results Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients gilead.com ↗
The study found that 78 percent of patients (n=161/207) remained HCV RNA undetectable 12 weeks after completing therapy (SVR12). |
| 2012-11-12 | Bristol-Myers Squibb | Results Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study bms.com ↗
The SVR12 rate for all genotype 1 infected patients in the Lambda/RBV/DCV group was 76% (28/37). |
| 2012-11-11 | Bristol-Myers Squibb | Results Investigational Hepatitis C Quad Therapy Regimen of Daclatasvir and Asunaprevir Plus Interferon Alfa and Ribavirin Achieved SVR24 in 93% of Difficult-to-Treat Genotype 1a/b Prior Null Responders in Expanded Phase II Study bms.com ↗ |
| 2012-11-10 | Boehringer Ingelheim | Results Phase 2b Data of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients prnewswire.com ↗
A viral cure was achieved for 69 percent of all patients included in the study (both GT1a and GT1b HCV infections), and includes patients with advanced liver disease that are more challenging to cure. |
| 2012-11-10 | Merck Sharp & Dohme LLC | Results Merck Reports New Phase III Analyses on Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy, Including Cirrhotic Patients merck.com ↗
SVR rates were generally similar regardless of when patients began ribavirin dose reduction, the number of steps of ribavirin dose reduction, or the lowest ribavirin dose of 400 to 1,000 mg/day received for at least 14 days for anemia management. |
| 2012-11-10 | Merck Sharp & Dohme LLC | Results Interim Phase II Data of Merck’s Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting merck.com ↗
The MK-5172 regimens had rates of cEVR ranging from 82.8 to 93 percent, versus the control of 74.2 percent. |
| 2012-11-10 | Gilead Sciences | Results Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients gilead.com ↗
Among treatment-naïve patients receiving this combination, 100 percent (n=25/25) remained HCV RNA undetectable four weeks after completing therapy (SVR4). |
| 2012-11-10 | Vertex Pharmaceuticals Incorporated | Results Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily vrtx.com ↗ |
| 2012-11-01 | Vertex Pharmaceuticals Incorporated | Results Vertex Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs vrtx.com ↗
Adverse events were generally similar between both arms of the study and consistent with previous studies. |
| 2012-10-16 | Bristol-Myers Squibb | Results Bristol-Myers Squibb to Present New Data Demonstrating Company’s Continuing Commitment to Research and Development in Liver Disease at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting bms.com ↗ |
| 2012-10-01 | Boehringer Ingelheim | Results New Hepatitis C Data from Boehringer Ingelheim to be Presented at AASLD Annual Meeting prnewswire.com ↗
Addition of the NS5B polymerase inhibitor BI 207127 to pegylated interferon and ribavirin (PegIFN/RBV) for 4 weeks followed by PegIFN/RBV for 44 weeks improves SVR24 rates in treatment-naive patients with HCV genotype (GT) 1 and is well tolerated |
| 2012-09-25 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158 vrtx.com ↗
Similar to previously announced data from the monotherapy cohort, ALS-2200 was well-tolerated, no patients discontinued due to adverse events and there were no serious adverse events. |
| 2012-04-19 | Boehringer Ingelheim | Results Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12) prnewswire.com ↗
Furthermore, a separate arm of the SOUND-C2 study showed that after 16 weeks of interferon-free treatment, SVR12 was achieved in 59 percent of patients. |
| 2012-04-19 | Boehringer Ingelheim | Results Phase 2b Data Show SVR12 in Cirrhotic HCV Patients Treated with Interferon-Free Regimen prnewswire.com ↗ |
| 2012-04-19 | Merck Sharp & Dohme LLC | Results Merck Reports Phase III Study Results Evaluating Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy merck.com ↗
The rates of SVR were 71 percent for both groups: those patients whose anemia was managed by ribavirin dose reduction (178/249) and those patients whose anemia was managed by the addition of erythropoietin (EPO) (178/251). |
| 2012-04-19 | Gilead Sciences | Results Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients gilead.com ↗
At the end of treatment, 51/51 patients (100 percent) were HCV RNA undetectable. |
| 2012-04-19 | Gilead Sciences | Results Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients gilead.com ↗
Of the 25 patients who completed 12 weeks of treatment with the GS-7977-based regimen, 88 percent of patients (n=22/25) remained HCV RNA undetectable four weeks after completion of treatment. |
| 2012-04-19 | Bristol-Myers Squibb | Results Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naïve Genotype 2 or 3 Hepatitis C Patients bms.com ↗
In this study, the investigational compound peginterferon lambda-1a (Lambda) plus ribavirin (RBV) achieved sustained virologic response rates 24 weeks post-treatment (SVR 24 ) that were comparable to peginterferon alfa-2a (alfa) plus ribavirin. |
| 2012-04-19 | Bristol-Myers Squibb | Results All-Oral Combination of Investigational Hepatitis C (HCV) Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response (SVR4) in 100% of Genotype 1 and 91% of Genotype 2 and 3 Treatment-Naïve Patients in Phase II Study bms.com ↗
In this interim analysis, a combination of the two oral, once-daily investigational compounds taken for 24 weeks, with or without ribavirin, achieved a rapid and sustained viral response. |
| 2012-04-18 | Vertex Pharmaceuticals Incorporated | Results Vertex Advances INCIVEK™ (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C vrtx.com ↗
Subanalysis of Phase 2 data shows 12 weeks of INCIVEK combination treatment resulted in a viral cure (SVR) for 100% of people with hepatitis C who had the IL28B CC genotype |
| 2012-03-06 | Merck Sharp & Dohme LLC | Results Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗
In the study, a higher percentage of patients receiving VICTRELIS in combination with peginterferon alfa-2b and ribavirin had undetectable hepatitis C virus (HCV-RNA) 12 weeks after treatment ended (sustained virologic response-12 1 or SVR-12) than patients receiving peginterferon alfa-2b and ribavirin alone. |
| 2012-03-06 | Vertex Pharmaceuticals Incorporated | Results Data from Phase 2 Study of an INCIVEK® Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12) vrtx.com ↗ |
| 2012-02-23 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C vrtx.com ↗
Nine of these 11 patients achieved SVR4 (undetectable hepatitis C virus four weeks after the end of all treatment). |
| 2012-02-17 | Gilead Sciences | Results Gilead Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study gilead.com ↗
Among these eight patients, six have experienced viral relapse. |
| 2012-01-18 | Bristol-Myers Squibb | Results First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published bms.com ↗
The study also demonstrated that 100 percent (10/10) of these difficult-to-treat patients dosed with quadruple therapy containing daclatasvir and asunaprevir in combination with PEG-Interferon alfa and ribavirin achieved SVR12. |
| 2011-11-08 | Boehringer Ingelheim | Results Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types prnewswire.com ↗
Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from two Phase 2 studies evaluating the combination of the company's protease inhibitor, BI 201335, with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naive genotype-1 (GT1) hepatitis C virus (HCV) patients. |
| 2011-11-07 | Boehringer Ingelheim | Results Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD prnewswire.com ↗
They show that BI 201335 plus BI 207127 with ribavirin suppressed the hepatitis C virus to undetectable levels in the majority of patients in this study. |
| 2011-11-07 | Medivir | Results Medivir’s partner Tibotec announced that final SVR24 results from phase IIb PILLAR study of TMC435 will be presented at the AASLD meeting today medivir.com ↗
Results from the final PILLAR analysis showed that TMC435 administered in combination with peginterferon α-2a and ribavirin (PR) resulted in significantly higher sustained virologic response (SVR) rates compared to placebo plus PR. |
| 2011-11-05 | Merck Sharp & Dohme LLC | Results Interim Data for Merck’s VICTRELISTM (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting merck.com ↗
In this interim analysis, 38 percent (16/42) of prior null responders achieved a sustained virologic response (SVR)1 when treated with VICTRELIS in combination with P/R. |
| 2011-11-05 | Vertex Pharmaceuticals Incorporated | Results Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting® vrtx.com ↗
Data showed 74 percent (28/38) of patients who were treated with INCIVEK (in-SEE-veck) combination therapy had undetectable hepatitis C virus (HCV RNA) at Week 24 of treatment compared to 55 percent (12/22) who were treated with pegylated-interferon and ribavirin alone. |
| 2011-11-05 | Vertex Pharmaceuticals Incorporated | Results Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR) vrtx.com ↗
Fifty percent (15/30) of patients who received the combination regimen including VX-222 (400mg) were eligible for a total of 12 weeks of treatment and 93 percent (14/15) of them achieved a viral cure (sustained viral response, or SVR). |
| 2011-10-20 | Merck Sharp & Dohme LLC | Results Interim Phase IIb Data for Merck’s VICTRELIS™ (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting merck.com ↗
These interim results are being presented for the first time in a late-breaker oral presentation at the Infectious Diseases Society of America (IDSA) 2011 annual meeting in Boston. |
| 2011-09-17 | Bristol-Myers Squibb | Results BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients bms.com ↗
In this Phase II study, adding BMS-790052 once daily to peginterferon alfa and ribavirin produced SVR rates and safety findings that warranted further development of BMS-790052. |
| 2011-09-14 | Vertex Pharmaceuticals Incorporated | Results New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK™ (telaprevir) in Hepatitis C vrtx.com ↗
In this study, 65 percent (352/540) of people had undetectable hepatitis C virus at weeks 4 and 12. |
| 2011-07-26 | Vertex Pharmaceuticals Incorporated | Results Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK™ Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks vrtx.com ↗
The hepatitis C virus was undetectable in 100 percent (13/13) of these patients at the end of 24 weeks. |
| 2011-04-02 | Bristol-Myers Squibb | Results Investigational Compound PEG-Interferon Lambda Achieved Higher Response Rates with Fewer Flu-Like and Musculoskeletal Symptoms and Cytopenias Than PEG-Interferon Alfa in Phase IIb Study of 526 Treatment-Naive Hepatitis C Patients bms.com ↗ |
| 2011-04-01 | Boehringer Ingelheim | Results Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients prnewswire.com ↗
Results from SILEN-C1 show a sustained viral response (SVR) in 71 to 83 percent of treatment-naive patients who received BI 201335 once-daily plus the current standard-of-care (SOC) [pegylated interferon (PegIFN) and ribavirin (RBV)]. |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Results Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful vrtx.com ↗
Data from the study showed that people in each of these subgroups who were treated with telaprevir-based combination therapy achieved superior rates of sustained viral response (SVR, or viral cure) compared to those treated with pegylated-interferon and ribavirin alone. |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Results Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C vrtx.com ↗
Among those who received VX-222 (400 mg) in combination with telaprevir, pegylated-interferon and ribavirin, interim data showed that 90 percent (27/30) of them had undetectable hepatitis C virus at week 12. |
| 2011-03-31 | Vertex Pharmaceuticals Incorporated | Results Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status vrtx.com ↗ |
| 2011-03-31 | Bristol-Myers Squibb | Results Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study of Treatment-Naïve Hepatitis C Patients bms.com ↗ |
| 2011-03-07 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 bms.com ↗
Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV Genotype 1 null responders (Late-Breakers Oral Session) |
| 2011-03-02 | Vertex Pharmaceuticals Incorporated | Results Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference vrtx.com ↗
HIV viral load and CD4 counts were stable among patients receiving a telaprevir-based regimen. |
| 2010-10-30 | Boehringer Ingelheim | Results Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon prnewswire.com ↗
In the lower and higher dose groups, 73 and 100% of patients achieved a rapid virological response (i.e. HCV RNA below lower limit of quantification after 4 weeks of treatment). |
| 2010-10-30 | Gilead Sciences | Results Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study gilead.com ↗
Gilead Sciences, Inc. (Nasdaq:GILD) today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment. |
| 2010-10-30 | Vertex Pharmaceuticals Incorporated | Results New Data From Phase 3 Studies Showed Superior SVR (Viral Cure) Rates Achieved with Telaprevir-Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease vrtx.com ↗ |
| 2010-10-01 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Compounds to be Presented at AASLD 2010 bms.com ↗
Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders |
| 2010-09-07 | Vertex Pharmaceuticals Incorporated | Results 65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study vrtx.com ↗ |
| 2010-08-10 | Vertex Pharmaceuticals Incorporated | Results Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment vrtx.com ↗
Sustained viral response (SVR or viral cure) rates of 92% and 88% were observed in the randomized 24 and 48-week telaprevir-based treatment groups, respectively. |
| 2010-05-25 | Vertex Pharmaceuticals Incorporated | Results 75% of Treatment-Naïve Patients with Chronic Hepatitis C Achieve SVR (Viral Cure) with Telaprevir-Based Treatment in Phase 3 Trial vrtx.com ↗
69% of people achieved SVR after receiving an 8-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone. |
| 2010-04-07 | Vertex Pharmaceuticals Incorporated | Results New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy vrtx.com ↗
In the trial, 51 percent and 53 percent of patients who received telaprevir in combination with pegylated-interferon and ribavirin as part of a 24-week or 48-week regimen, respectively, achieved SVR. |
| 2009-10-31 | Vertex Pharmaceuticals Incorporated | Results More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens vrtx.com ↗
For the majority of patients, these SVR rates were obtained with a 24-week telaprevir-based regimen. |
| 2009-10-31 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C bms.com ↗
Antiviral activity was observed at all dose levels tested. |
| 2009-09-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting vrtx.com ↗
Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response (SVR) in "Difficult-to-Cure" Patients With Chronic Hepatitis C (CHC): a Pooled Analysis From the PROVE 1 and PROVE 2 Trials |
| 2009-04-29 | Vertex Pharmaceuticals Incorporated | Results New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir vrtx.com ↗
telaprevir dosed in combination with pegylated-interferon (peg-IFN) and ribavirin (RBV) as part of a 24-week treatment regimen resulted in a significant improvement in the rate of sustained viral response (SVR) |
| 2009-04-28 | Debiopharm International SA | Results Clinical Update – Debio025 in Hepatitis C – Debiopharm presents promising phase IIa results showing potent antiviral activity debiopharm.com ↗ |
| 2009-04-24 | Bristol-Myers Squibb | Results Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C bms.com ↗
Antiviral activity was observed at all dose levels tested either as single agent or in combination with ribavirin. |
| 2009-04-21 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir's Potential for Use in a Broad Range of HCV Patients and Highlighting the Company's Expanded STAT-C Portfolio vrtx.com ↗
Interim data from two Phase 2 studies (C209 and C210) in treatment-naïve HCV patients show substantial antiviral activity against HCV genotypes 2 and 4 when telaprevir is combined with the standard of care compared with standard of care alone. |
| 2008-11-01 | Vertex Pharmaceuticals Incorporated | Results New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection vrtx.com ↗
The PROVE 3 data show a 52% SVR12 in HCV treatment-failure patients, with a 24-week treatment duration. |
| 2008-09-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatology vrtx.com ↗
The correctly labeled table, and the corresponding HCV RNA results, are provided below: |
| 2008-06-09 | Vertex Pharmaceuticals Incorporated | Results Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment vrtx.com ↗ |
| 2008-04-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment vrtx.com ↗
In the interim analysis, patients treated with telaprevir in combination with peg-IFN and RBV demonstrated a high rate of viral response at week 4 (49 of 60 patients achieved HCV RNA 25 IU/mL). |
| 2008-04-23 | Vertex Pharmaceuticals Incorporated | Results Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments vrtx.com ↗ |
| 2007-07-24 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports Second Quarter 2007 Financial Results and Provides Development Pipeline Update vrtx.com ↗
Among the patients who completed 24 weeks of therapy and had undetectable HCV RNA (less than 10 IU/mL) at the end of treatment, fewer than 10 percent had relapsed by the end of 12 weeks post-treatment follow-up. |
| 2007-06-12 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports 2007 Pipeline Progress vrtx.com ↗
At this time, Vertex is reporting that the preliminary results are consistent with findings reported for PROVE 1. |
| 2006-10-27 | Vertex Pharmaceuticals Incorporated | Results New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting vrtx.com ↗
Clinical investigators will also report that some of these patients have stopped therapy, and that a proportion of them continued to have undetectable HCV RNA after stopping therapy. |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Results Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗
Researchers reported for the first time today that 11 of these patients (92%) continue to have no detectable virus in their blood at the end of 12 additional weeks of follow-on peg-IFN+RBV dosing. |
| 2006-04-29 | Vertex Pharmaceuticals Incorporated | Results Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients vrtx.com ↗
Researchers reported for the first time today that 8 of 8 patients who received VX-950 and peg-IFN in combination for 14 days have no detectable virus in their blood at the end of 12 additional weeks of peg-IFN+RBV dosing. |
| 2006-02-07 | Vertex Pharmaceuticals Incorporated | Results Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program vrtx.com ↗
Plasma HCV RNA levels are less than 10 IU/mL in 12 of 12 patients after 28 days of dosing with VX-950/peg-IFN/RBV in Phase II study |
| 2006-02-06 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports 2005 Financial Results vrtx.com ↗
In the study, 12 of 12 patients had plasma HCV RNA levels below the limits of detection of a highly sensitive assay (10 IU/mL; Roche TaqMan®) at 28 days of dosing. |
| 2005-12-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Final Approval Of Ribavirin Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Ribavirin Tablets, 200 mg. |
| 2005-09-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval of Ribavirin Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Ribavirin Tablets, 200 mg. |
| 2004-10-04 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval Of Ribavirin Capsules tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Ribavirin Capsules, 200 mg. |
| 2004-05-04 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV vrtx.com ↗
Researchers also observed antiviral synergy in two triple combinations consisting of MMPD + interferon alpha + ribavirin and MMPD + interferon alpha + VX-950 in two-day replicon assays. |
| 2004-04-16 | Vertex Pharmaceuticals Incorporated | Results Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches vrtx.com ↗
results for patients enrolled in the extension phase of a pilot Phase IIa study designed to evaluate the safety and tolerability of merimepodib in combination with peg-IFN and ribavirin |
All press releases naming this drug 164 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 164 releases opens the full record — a long page | ||
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 805 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ribavirin | “This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for...” NCT01908335 ↗758“The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose...” NCT02536313 ↗ “The primary objective of this study is to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) with ribavirin (RBV) for...” NCT02300103 ↗ “This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) +...” NCT02226549 ↗ “Day 1 (First 24 hours): IV Ribavirin (33mg/kg) loading dose followed by IV Ribavirin 16mg/kg every 6 hours Day 2 (24-48 hours): IV Ribavirin 16mg/kg four times daily (QDS) Days...” NCT06860334 ↗ “This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA)...” NCT01903278 ↗ “The primary objective of this study was to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without...” NCT02487030 ↗ “Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus...” NCT01625793 ↗ “AIM: To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and...” PMID 27062488 ↗ Jun 2016 “We conducted a clinical trial using the DAA sofosbuvir plus ribavirin (SOF/RBV) and performed detailed mRNA expression analysis in liver and peripheral blood from patients who...” PMID 24983321 ↗ Jul 2014 “Patients received a combination of ritonavir-boosted danoprevir (100 mg/100 mg) twice a day plus subcutaneous injection of weekly pegylated-interferon α-2a (180 μg) and oral...” PMID 31608213 ↗ Jul 2019 |
| Known as | (b) SCH 18908, PEGETRON (ribavirin) Capsules | “(b) SCH 18908, PEGETRON® (ribavirin) Capsules” NCT00423800 ↗ |
| Known as | Copegus | “Pegylated interferon plus ribavirin is the standard first-line treatment in patients with chronic hepatitis C virus (HCV) mono-infection. Although the optimal anti-HCV regimen...” PMID 15563253 ↗ 200452“A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group...” NCT00535847 ↗ “A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and...” NCT00983853 ↗ “Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.” NCT00107653 ↗ “PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.” NCT00077636 ↗ “RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration.” NCT02340962 ↗ “Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day” NCT00532701 ↗ “Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID” NCT01435226 ↗ “Peg-IFN alfa2a (Pegasys) and Ribavirin (Copegus) or Peg-IFN alfa2b (PegIntron) and Ribavirin (Rebetol)” NCT00528528 ↗ “PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin)” NCT00087646 ↗ “GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 24 weeks.” NCT01353248 ↗ |
| Known as | COPEGUS (RIBAVIRIN) | “COPEGUS (RIBAVIRIN)” NCT00909129 ↗ |
| Known as | RBV | “This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for...” NCT01908335 ↗190“This is an exploratory study and is a Phase 3, single-arm, multi-center, open-label study of pegylated interferon alfa-2b, PEG-IFN alpha-2b (PEG-Intron) and ribavirin (RBV) to...” NCT00378599 ↗ “The primary objective of this study is to evaluate the efficacy, safety and tolerability of treatment with sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) with ribavirin (RBV) for...” NCT02300103 ↗ “The purpose of this study is to determine the effectiveness, safety and tolerability of telaprevir administered as 750 mg every 8 hours (q8h) in combination with pegylated...” NCT01498068 ↗ “This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) +...” NCT02226549 ↗ “The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin...” NCT01370642 ↗ “The proposed study will quantify hepatic improvement and antiviral efficacy of the open-label interferon-free combination of 12 weeks of simeprevir (SMV, Simeprevir),...” NCT02455167 ↗ “METHODS: A subanalysis of efficacy and safety for a daclatasvir (DCV) and sofosbuvir (SOF) regimen, with or without ribavirin (RBV), was undertaken in HIV-HCV-coinfected...” PMID 27845298 ↗ Nov 2016 “This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin...” NCT01500772 ↗ “Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the present phase II study was to examine virologic...” PMID 22473713 ↗ Jul 2012 “This study is to confirm the potential effects and assess the safety of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA)...” NCT01903278 ↗ |
| Known as | RBV: Copegus (Hoffman La-Roche) | “RBV: Copegus (Hoffman La-Roche)” NCT00977054 ↗ |
| Known as | Rebetol | “Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily...” NCT01838772 ↗14“in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight” NCT00956982 ↗ “Peg-IFN alfa2a (Pegasys) and Ribavirin (Copegus) or Peg-IFN alfa2b (PegIntron) and Ribavirin (Rebetol)” NCT00528528 ↗ “treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)” NCT03547895 ↗ “Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol” NCT00367887 ↗ “Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules” NCT00135798 ↗ “REBETOL is the Schering-Plough brand name for ribavirin.” NCT00081770 ↗ “Rebetol® (ribavirin), 1000/1200mg by mouth daily” NCT01949168 ↗ “Ribavirin (Rebetol)” NCT00207363 ↗ |
| Known as | REBETOL [the Schering-Plough brand name for ribavirin] | “REBETOL [the Schering-Plough brand name for ribavirin]” NCT00081770 ↗ |
| Known as | Rebetol, Schering-Plough) | “Rebetol, Schering-Plough)” NCT00556504 ↗ |
| Known as | RIB | “ribavirin (RIB) was given for 12 weeks.” NCT03499639 ↗ |
| Known as | Ribasphere | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01795911 ↗ |
| Known as | Ribavirin (COPEGUS) | “Ribavirin (COPEGUS)” NCT01289496 ↗ |
| Known as | Ribavirin (Copegus, F. Hoffman-LaRoche) | “Ribavirin (Copegus, F. Hoffman-LaRoche)” NCT00491244 ↗ |
| Known as | Ribavirin (RBV) | “Ribavirin (RBV)” NCT01052701 ↗ |
| Known as | Ribavirin Capsules | “Drug: Ribavirin Capsules” NCT04828564 ↗ |
| Known as | Ribavirin: Rebetol | “Ribavirin: Rebetol” NCT01457937 ↗ |
| Known as | Ribavirine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00199719 ↗ |
| Known as | Ro20-9963 | “A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C” NCT00144469 ↗ |
| Known as | SCH 018908 | “Ribavirin (SCH 018908)” NCT00687544 ↗1“Ribavirin (SCH 018908)” NCT00724620 ↗ |
| Known as | SCH 18908 | “PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with...” NCT00081770 ↗3“REBETOL (ribavirin; SCH 18908)” NCT00039871 ↗ “Ribavirin (SCH 18908)” NCT00708500 ↗ “Ribavirin (SCH 18908)” NCT00910624 ↗ |
| Known as | Vilona | “ribavirin [Vilona]” NCT01615393 ↗ |
| Known as | Virazole | “50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.” NCT04356677 ↗6“Virazole (Ribavirin) Inhalation Solution” NCT00031473 ↗ “Ribavirin (Virazole) Injection” NCT00992693 ↗ |
| Known as | Virazole (Ribavirin); | “Virazole (Ribavirin);” NCT02455167 ↗ |
| Action | Inhibit | “ribavirin appears to inhibit the spread of the virus” NCT00000733 ↗ |
| Modality | Small molecule | “RBV is another antiviral nucleotide analogue with few adverse effects” NCT00117533 ↗ |
| Route | Oral | “All patients take INPX capsules 4 times a day and RBV capsules 2 or 3 times a day.” NCT00000699 ↗ |
| Target | EIF4E | “Ribavirin impedes eIF4E mediated transformation in vitro, in primary human specimens and in animal models.” NCT00559091 ↗ |